|
2023 Conference Publication Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC CohortAn, Y. K., Lindsay, N., Allan, N., Khoo, E., Fernandes, R., Amiss, A., Pham, H., Wong, K. F., Ooi, S. Y., Thin, L., Lightowler, D., Connor, S. J., Williams, A. J., De Cruz, P., Suen, C. Li Wai, Kariyawasam, V., Mitrev, N., Ghaly, S., Andrews, J. M., Christensen, B., Sparrow, M. P., White, L. S., Bryant, R. V., Ding, N., Leong, R., Van Langenberg, D., Seltenreich, H., Subramaniam, K., Radford-Smith, G. and Begun, J. (2023). Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0793 |
|
2023 Conference Publication Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trialPudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. OXFORD: OXFORD UNIV PRESS. |
|
2023 Conference Publication Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trialPudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0543 |
|
2023 Conference Publication Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohortAn, Y. K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A., Begun, J. and Gastroenterology Network of Intestinal Ultrasound (GENIUS) (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0744 |
|
2022 Journal Article Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosisMalloy, Reuben, Fernandes, Richard, Begun, Jakob and An, Yoon-Kyo (2022). Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. BMJ Case Reports, 15 (12) 252140, e252140. doi: 10.1136/bcr-2022-252140 |
|
2022 Conference Publication Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium CohortAn,Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Amiss, Anna, Moniruzzaman, Md, Fernandes, Richard, Ooi, Soong-Yuan J., Thin, Lena W.Y., Mstj, Daniel Lightowler, Connor, Susan, Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nicola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren, Bryant, Robert, Ding, Nik S., Leong, Rupert W., Van Langenberg, Daniel R., Seltenreich, Hans, Subramaniam, Kavitha, Radford-Smith, Graham and Begun, Jakob (2022). Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9–11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.15953 |
|
2022 Conference Publication Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic RemissionPudipeddi, Aviv, Fung, Caroline, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon, Begun, Jakob, Connor, Susan, Chetwood, John, Paramsothy, Sudarshan and Leong, Rupert (2022). Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic Remission. International Digestive Disease Forum (IDDF), Hong Kong, China, 2-4 September 2022. London, United Kingdom: BMJ Group. doi: 10.1136/gutjnl-2022-IDDF.207 |
|
2021 Journal Article Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulasDe Gregorio, Michael, Lee, Tanya, Krishnaprasad, Krupa, Amos, Gregory, An, Yoon-Kyo, Bastian-Jordan, Matthew, Begun, Jakob, Borok, Nira, Brown, Dougal J. M., Cheung, Wa, Connor, Susan J., Gerstenmaier, Jan, Gilbert, Lauren E., Gilmore, Robert, Gu, Bonita, Kutaiba, Numan, Lee, Allan, Mahy, Gillian, Srinivasan, Ashish, Thin, Lena, Thompson, Alexander J., Welman, Christopher J., Yong, Eric X. Z., De Cruz, Peter, van Langenberg, Daniel, Sparrow, Miles P. and Ding, Nik S. (2021). Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas. Clinical Gastroenterology and Hepatology, 20 (6), 1306-1314. doi: 10.1016/j.cgh.2021.07.053 |
|
2021 Conference Publication Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre studyDe Gregorio, M., Lee, T., Krishnaprasad, K., Amos, G., An, Y. K., Bastian-Jordan, M., Begun, J., Borok, N., Brown, D. J. M., Cheung, W., Connor, S., Gerstenmaier, J., Gilbert, L. E., Gilmore, R., Gu, B., Kutaiba, N., Lee, A., Mahy, G., Srinivasan, A., Thin, L., Thompson, A., Welman, C. J., Yong, E. X., De Cruz, P., van Langenberg, D., Sparrow, M. and Ding, N. S. (2021). Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study. 16th Congress of ECCO, Online, 2-3 & 8-10 July 2021. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjab076.523 |
|
2021 Conference Publication Risks of under-treating and over-treating diseaseAn, Yoon-Kyo (2021). Risks of under-treating and over-treating disease. IBD 2020: Right Therapy, Right Patient, Right Time#Choosing Wisely, Proceedings of the Takeda IBD Symposium, Virtual, 5 September 2020. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.15458 |
|
2020 Journal Article Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort studyHaifer, Craig, Srinivasan, Ashish, An, Yoon‐Kyo, Picardo, Sherman, Langenberg, Daniel, Menon, Shankar, Begun, Jakob, Ghaly, Simon and Thin, Lena (2020). Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Medical Journal of Australia, 214 (3) mja2.50824, 128-133. doi: 10.5694/mja2.50824 |
|
2020 Journal Article Monitoring inflammatory bowel disease in pregnancy using gastrointestinal ultrasonographyFlanagan, Emma, Wright, Emily K., Begun, Jakob, Bryant, Robert V., An, Yoon-Kyo, Ross, Alyson L., Kiburg, Katerina V. and Bell, Sally J. (2020). Monitoring inflammatory bowel disease in pregnancy using gastrointestinal ultrasonography. Journal of Crohn's and Colitis, 14 (10), 1405-1412. doi: 10.1093/ecco-jcc/jjaa082 |
|
2019 Journal Article Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta‐analysisAn, Yoon‐Kyo, Prince, David, Gardiner, Fergus, Neeman, Teresa, Linedale, Ecushla C., Andrews, Jane M., Connor, Susan and Begun, Jakob (2019). Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta‐analysis. Medical Journal of Australia, 211 (10) mja2.50384, 461-467. doi: 10.5694/mja2.50384 |
|
2019 Journal Article Gastrointestinal ultrasound in inflammatory bowel disease care: patient perceptions and impact on disease‐related knowledgeRajagopalan, Arvind, Sathananthan, Dharshan, An, Yoon‐Kyo, Van De Ven, Lucinda, Martin, Serena, Fon, James, Costello, Samuel P, Begun, Jakob and Bryant, Robert V (2019). Gastrointestinal ultrasound in inflammatory bowel disease care: patient perceptions and impact on disease‐related knowledge. JGH Open, 4 (2) jgh3.12268, 267-272. doi: 10.1002/jgh3.12268 |
|
2019 Journal Article Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitisChoy, Matthew C., Seah, Dean, Faleck, David M., Shah, Shailja C., Chao, Che-Yung, An, Yoon-Kyo, Radford-Smith, Graham, Bessissow, Talat, Dubinsky, Marla C., Ford, Alexander C., Churilov, Leonid, Yeomans, Neville D. and De Cruz, Peter P. (2019). Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitis. Inflammatory Bowel Diseases, 25 (7), 1169-1186. doi: 10.1093/ibd/izy383 |
|
2019 Conference Publication Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort studyHaifer, C., Srinivasan, A., Menon, S., An, Y., Picardo, S., Van Langenberg, D., Begun, J., Ghaly, S. and Thin, L. (2019). Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “The Universe Within”, Adelaide, SA, Australia, 8–10 September 2019. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.14801 |
|
2019 Conference Publication Effectiveness of fecal calprotectin testing to identify patients with organic gastrointestinal diseases: a systematic review and diagnostic meta-analysisAn, Y., Prince, D., Gardiner, F., Linedale, E., Andrews, J., Connor, S. and Begun, J. (2019). Effectiveness of fecal calprotectin testing to identify patients with organic gastrointestinal diseases: a systematic review and diagnostic meta-analysis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “The Universe Within”, Adelaide, South Australia, 8-10 September 2019. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.14803 |
|
2018 Journal Article Predicting response after infliximab salvage in acute severe ulcerative colitisChoy, Matthew C., Seah, Dean, Gorelik, Alexandra, An, Yoon-Kyo, Chen, Cheng-Yu, Macrae, Finlay A., Sparrow, Miles P., Connell, William R., Moore, Gregory T., Radford-Smith, Graham, Van Langenberg, Daniel R. and De Cruz, Peter (2018). Predicting response after infliximab salvage in acute severe ulcerative colitis. Journal of Gastroenterology and Hepatology, 33 (7), 1347-1352. doi: 10.1111/jgh.14072 |
|
2016 Conference Publication Demyelination during infliximab therapy for crown's diseaseAn, Y. K., Allsop, S., Daveson, K.L. and Daveson, A. J. M. (2016). Demyelination during infliximab therapy for crown's disease. Australian Gastroenterology Week, Adelaide, SA, Australia, 10–12 October 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.13522 |
|
2016 Conference Publication The incidence of 30-day adverse events after colonoscopy in an IBD populationAn, Y. K., Wong, J., You, I. S., Mortimore, M., Hewett, D. G., Appleyard, M. N. and Begun, J. (2016). The incidence of 30-day adverse events after colonoscopy in an IBD population. Gastroenterological Society of Australia, Australian Gastroenterology Week 2016, Adelaide, South Australia, Australia, 10–12 October 2016. HOBOKEN: WILEY-BLACKWELL. doi: 10.1111/jgh.13522 |
